Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 4/20 | 0.36 |
| ▸ | EP300 | Q09472 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.34 |
| ▸ | NNMT | P40261 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
| ▸ | HTR7 | P34969 | 1/20 | 0.31 |
| ▸ | HTR5A | P47898 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TNF | P01375 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31170704 | 0.83 | HTR2C (0.40) | HTR2CHTR2BHTR2APGR | |
| SCHEMBL11172350 | 0.83 | HTR2C (0.40) | HTR2CHTR2BHTR2APGR | |
| SCHEMBL9035367 | 0.81 | BRD4 (0.37) | BRD4CREBBPEP300CYP2C9ADORA3 | |
| SCHEMBL9035052 | 0.81 | NOTUM (0.44) | HTR2CHTR2BHTR2ABRD4CREBBP | |
| SCHEMBL9582635 | 0.81 | NOTUM (0.44) | HTR2CHTR2BHTR2ABRD4CREBBP | |
| SCHEMBL9582630 | 0.81 | BRD4 (0.37) | BRD4CREBBPEP300CYP2C9ADORA3 | |
| SCHEMBL9703779 | 0.77 | BRD4 (0.38) | BRD4CREBBPEP300CYP2C9ADORA3 | |
| SCHEMBL13745465 | 0.76 | HTR2A (0.41) | HTR2CHTR2BHTR2ABRD4CREBBP | |
| SCHEMBL12475566 | 0.74 | CREBBP (0.44) | BRD4CREBBPEP300RAB9AHTR5A | |
| SCHEMBL15311967 | 0.74 | CREBBP (0.44) | BRD4CREBBPEP300RAB9AHTR5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| EP-2658844-B1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI SA (FR) | 2016-10-26 | — | — | EP | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-9133168-B2 | Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors | SANOFI (FR) | 2015-09-15 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | SANOFI (FR) | 2013-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274253-A1 | NOVEL PYRIMIDINE DERIVATIVES, PREPARATION THEREOF, AND PHARMACEUTICAL USE THEREOF AS AKT(PKB) PHOSPHORYLATION INHIBITORS | TYMP, PIK3CA, PDPK1 | HTR2C 3622/4885HTR2B 2104/4885HTR2A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.